Delcath Systems (NASDAQ:DCTH) specializes in precision oncology, focusing on the development and commercialization of innovative treatments for primary and metastatic cancers of the liver. The company is known for its proprietary percutaneous hepatic perfusion (PHP) technology, aimed at isolating the liver's blood flow and delivering high doses of anti-cancer drugs to the liver while minimizing systemic exposure. This unique approach allows for targeted treatment of liver cancers, potentially improving patient outcomes and reducing side effects compared to traditional systemic chemotherapy. Delcath Systems is committed to advancing its research and development initiatives to address the unmet needs in liver cancer treatment, striving to improve survival rates and the quality of life for patients facing this challenging disease.